Stocks · News reference
Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and lowers the price target from $72 to $58.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Liquidia Corporation announced it will release its third quarter 2026 financial results on November 10, 2026, followed by a live webcast to discuss the results and provide a corporate update.
RBC analysts noted that United Therapeutics' outlook for its Tyvaso product faces near-term pressure following a settlement agreement with Liquidia.
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $58 to $65.
US stocks fell Wednesday as Nasdaq dropped 1.54% and Dow 0.35%; Bank of America sank 5% after weak results, while oil rose and inflation topped forecasts.
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Equal-Weight and raises the price target from $30 to $33.
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.